August 22, 2005
ST. LOUIS, MO – RiverVest Venture Partners®, a venture capital firm investing nationwide in emerging medical technology and biopharmaceutical companies, today announced that Gordon Foulkes, Ph.D., has joined the firm as a Venture Partner. Dr. Foulkes brings to RiverVest extensive operational experience in biopharmaceutical research and development. Prior to joining RiverVest, he headed research and development in three biotechnology companies where he helped raise $145 million in private and public offerings and secure more than $200 million in 15 corporate partnerships.
Read More…
August 15, 2005
ST. LOUIS, MO – RiverVest Venture Partners®, a venture capital firm investing nationwide in emerging medical technology and biopharmaceutical companies, has named Dennis Wahr, M.D., to the position of managing director. Wahr, a specialist in cardiac medicine, brings to the firm more than 25 years of experience in clinical practice and medical device entrepreneurship. He is a former practicing interventional cardiologist and founder of Velocimed, LLC, where he served as president and CEO until the recent acquisition of the company’s business by St. Jude Medical.
Read More…
May 1, 2002
ST. LOUIS, MO – RiverVest Venture Partners, a national venture capital firm focusing on seed and early-stage life sciences investments, has named Scott R. Naisbitt, M.D., Ph.D. an associate and Floyd E. Bloom, M.D., a scientific advisor.
Read More…
October 19, 2001
ST. LOUIS, MO – RiverVest Venture Partners announced today that the fundraising for RiverVest Venture Fund I, L.P. is complete, closing with $89 million of capital under management. The firm’s founders and managing directors are Andrew B. Craig III, Thomas C. Melzer, Jay W. Schmelter and Mark J. Mendel, Ph.D.
Read More…
